For adults and children with hemophilia B

LONG-LASTING
BLEED PROTECTIONFOR THE EXPLORER WITHIN

#1 FACTOR IX MOST PRESCRIBED FOR PROPHYLAXIS*

   ONLY IDELVION DELIVERS  

Zero spontaneous bleeds

Patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing*

EXPLORE IDELVION
EFFICACY
plus
7-and 14-day dosing with FDA approved*

Two dosing schedules that meet your patient's individual needs

VIEW FULL
DOSING INFORMATION
plus
20% though levels with prophylactic use

High and sustained Factor IX levels in clinical trials

DISCOVER HIGH FACTOR IX LEVELS

*Of the 23 subjects in Arm 2, 19 were transitioned from on-demand to 7-day prophylaxis. The median AsBR during prophylaxis treatment was 0.7 (range: 0 to 4.2). Data for Arms 1 and 2 based on matched-pairs design.

†Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.

Print the enrollment form

So your patients can see if it’s right for them

Resources for your patients through IDELVION ConnectSM

$0 for 95% of patients

Over 95% of commercially insured patients paid $0 for IDELVION through the co-pay program in 2020.4

CSL Behring is committed to providing treatment and support services that make a meaningful difference in the lives of people with bleeding disorders.

Resources are available to help your eligible patients get the treatment they need for hemophilia B, including:

  • A free trial of IDELVION
  • Co-pay assistance§
  • Lapse-in-coverage support with the CSL Behring AssuranceSM program
  • Reimbursement and access support

§Enrollment required. Terms and conditions apply. Visit here to learn more.

∥Terms, conditions, and limitations apply. Visit here to view terms and conditions.

References: 1. Data on file. Available from CSL Behring as DOF IDL-006. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 3. Data on file. Available from CSL Behring as DOF IDL-003. 4. Data on file. Available from CSL Behring as DOF IDL-009.

Have additional questions?

Connect with CSL Behring Medical Affairs to
find additional information and ask questions.

X
You are now leaving the current website.

Do you want to continue?